| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
3 companies
Mpm Bioventures 2018, L.P. is a 10% Owner at AKTS, with reported holdings spanning 3 companies. Recent filings cover 2 purchases and 14 sales. Those positions are worth an estimated $27.7M at current prices.
Our model assigns Mpm Bioventures 2018, L.P. a middling insider score of 54/100, based on 4 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +26.7%.
Mpm Bioventures 2018, L.P.'s largest disclosed position is in TRDA as 10% Owner, worth about $27.7M. The recent filings there lean toward selling, a net 440,669 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Sell | 259,837 | $7.33 | $1,905,767.81 | -6.3% | - | - | |
| Sep 3, 2026 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Sell | 86,482 | $7.14 | $617,378.88 | -2.0% | - | - | |
| Aug 31, 2026 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Sell | 86,914 | $7.08 | $615,777.14 | -2.0% | - | - | |
| Aug 26, 2026 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Sell | 62,714 | $7.36 | $461,545.84 | -1.4% | - | - | |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | 10% Owner | Buy | 1,112,777 | $18.00 | $20,029,986.00 | +12.2% | -20.3% | - | |
| Dec 11, 2024 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Sell | 44,722 | $20.51 | $917,110.96 | -1.0% | -46.5% | -45.7% | |
| Nov 2, 2021 | TRDA Entrada Therapeutics, Inc. | 10% Owner | Buy | 100,000 | $20.00 | $2,000,000.00 | +2.3% | -56.6% | -14.1% |